Загрузка...
Treatment discontinuation and re-initiation of anti-PD-(L)1 agents in metastatic cancers
INTRODUCTION: Immune checkpoint inhibitors (ICIs) are approved in multiple indications for cancer care. Most of the clinical trials have not questioned shorter than until disease progression approaches. In this study, we present results from a cohort of multiple advanced cancers treated with restric...
Сохранить в:
| Опубликовано в: : | J Cancer Res Clin Oncol |
|---|---|
| Главные авторы: | , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Springer Berlin Heidelberg
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7324422/ https://ncbi.nlm.nih.gov/pubmed/32306129 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00432-020-03217-7 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|